Skip to main content

Mazumdar Claire's Form 4 filing

Bicara Therapeutics Inc. (BCAX) · filed Oct 15, 2025

Accession no.
0002034671-25-000003
Filed
Oct 15, 2025
Trade date
Oct 13-15, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $466.9K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mazumdar ClaireCIK 0002034671Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 13, 2025Common StockMOption exerciseAcquired+11,445$3.79+$43,376.55321,337Direct
Oct 13, 2025Common StockSSaleDisposed−11,445$18.92−$216,539.4309,892Direct
Oct 15, 2025Common StockMOption exerciseAcquired+13,289$3.79+$50,365.31323,181Direct
Oct 15, 2025Common StockSSaleDisposed−13,289$18.84−$250,364.76309,892Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 13, 2025Common StockMOption exerciseDisposed−11,445$0.00$0314,662Direct
Oct 15, 2025Common StockMOption exerciseDisposed−13,289$0.00$0301,373Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)